Protext Pharma, Inc.
(fka Protext Mobilty, Inc.)
OTCPK: TXTM
Quarterly Report
For the period ending June 30, 2017

Item I - The exact name of the issuer.

Protext Pharma, Inc. (hereinafter referred to as "we", "us", or "our" or "issuer").
Name used by predecessor entities in the past 5 years: Protext Mobility, Inc.

Item II - The address of the issuer's principal executive offices.

2255 Glades Road, #324A and #319A
Boca Raton, Florida 33431
Phone: (435)881-3611
Email: info@Protextm.co
Website: www.Protextm.co

Item III - The exact title and class of securities outstanding.

Common Stock - Cusip # 74371E204
Trading symbol: TXTM
Par Value: $0.00001
Total Authorized 10,000,000,000
Total Outstanding: 3,089,879,479 as of June 30, 2017

Transfer Agent:
ClearTrust, LLC
16540 Pointe Village Dr, Ste 210
Lutz, FL 33558
Phone: 813.235.4490
www.ClearTrustOnline.com

Our transfer agent is registered under the Exchange Act, and is regulated by the Securities and Exchange Commission.

Preferred Stock – We have four classes of preferred stock, designated Series A through D

Series A – Par value $0.001, 100,000 shares authorized.

As a class, the Series A Preferred can convert into that number of common shares equal to 20% of the post-conversion issued and outstanding shares of common stock. Individual shares of Series A Preferred may convert into that pro-rata number of common shares equal to 1/100,000 of the total shares issuable to the entire class. The Series A Preferred has rights voting rights equal to that number of common shares into which the class is convertible on all shareholder matters. The Series A Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series A Preferred stockholders.

Series B – Par value $0.0001, 1,000,000 shares authorized.
Each share of Series B Preferred has voting rights equal to two votes on all shareholder matters. The Series B Preferred Stock converts to common stock on a 100:1. There are no other material rights of the Series B Preferred stockholders.

Series C – Par value $0.001, 10,000,000 shares authorized.
Each share of Series C Preferred has voting rights equal to 200 votes on all shareholder matters. The Series C Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series C Preferred stockholders.

Series D – Par value $0.001, 100,000 shares authorized.
As a class, the Series D Preferred can convert into that number of common shares equal to 75% of the post-conversion issued and outstanding shares of common stock. Individual shares of Series D Preferred may convert into that pro-rata number of common shares equal to 1/100,000 of the total shares issuable to the entire class. The Series D Preferred has rights voting rights equal to that number of common shares into which the class is convertible on all shareholder matters. The Series D Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series D Preferred stockholders.

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None.

Acquisition: Yes. Plandai Biotechnology South Africa (Pty) Ltd. in December, 2016 and Cannabis Biosciences, Inc. on March 14, 2017.

Item IV - Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons.

> During 2015, the Company issued 344,917,800 restricted common shares upon conversion of convertible notes and associated interest of $16,545.89
>
> During 2016 the Company issued 222,000,000 restricted common shares to settle certain of the Company's convertible debt and associated interest of $8,595.

On December 31, 2016, the Company issued 79,450 shares of Series A Preferred on the exchange of 504,003 shares of Series B Preferred. Simultaneously, we issued 100,000 shares of Series D Preferred in exchange for all of the outstanding capital of Plandaí Biotechnology South Africa (Pty) Ltd.

During the six months ended June 30, 2017, the Company had the following stock transactions:

- $46,750 was raised through the sale of 31,000,000 shares of common stock, which had not been issued as of June 30, 2017
- Cannabis Biosciences, Inc. was acquired in exchange for 50,000,000 shares of common stock, which had not been issued as of June 30, 2017.
- 45,000,000 shares were issued for consulting services valued at $58,500
- 1,078,189,155 shares were issued on the conversion of $176,744 in notes payable.

Item V - Financial Statements

Financial statements for the quarter ended June 30, 2017 are attached hereto.

Item VI - Describe the Issuer's Business, Products and Services

Protext Mobility Inc. was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, Protext Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters.

As a result of the transaction with Plandaí, the shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. While Plandaí is a legal subsidiary of the Company, Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes.

The Company at no time in its history has been a shell. There has never been a filing in bankruptcy, receivership The issuer is not now nor has it ever been a shell company. There is no pending or threatened legal action. There have not been any defaults on any notes, loans, leases or other obligations. The company's stock has never been delisted by any securities exchange or by the OTC Bulletin Board. Since inception, there has been no forward splits of the company's stock, stock dividend, recapitalization, reorganization, or spin off. On February 5th, 2014, the Company completed a 1 for 800 reverse stock split. The company has been in continuous operations since inception.

<u>Business Description:</u>

The issuer's primary and secondary SIC codes:

Primary Code: 2833
Secondary Code: 2834

Following the Share Exchange Agreement completed December 31, 2016, the Company's operations became those of Plandaí Biotechnology South Africa (Pty) Ltd. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Products

The Company focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Marketing

Following successful clinical trials, the Company will produce a finished product, expected to consist of a gel-cap or twin-capsule containing Phytofare® and/or Phytofare® mixed with other ingredients. We anticipate that these capsules will be marketed through various distributors to retail manufacturers for private label products.

The benefit of conducting human clinical trials is that, if successful, the Company can then apply for "claims" from the FDA and other international oversight agencies respecting the use of our products for treating one or more conditions or diseases. The types of claims that can be sought and awarded vary country-by-country; however, the awarding of claims enables the Company to market the product for specific applications rather than simply for "general wellness." This creates a significant competitive advantage over generic extracts and other branded ingredients. Our marketing efforts will, to a large degree, be dictated by the nature of claims awarded and will be largely country-specific.

In addition to the use of distributors, we may employ direct sales representatives in certain areas, participate in trade shows, and purchase media spots where appropriate. Direct-to-consumer sales are not part of the initial marketing strategy owing to the high cost associated with marketing a single product to consumers and buying and stocking retail space.

Item VII - Facilities.

The Company presently leases executive offices at 2255 Glades Road, Suites 324A and 319A, Boca Raton, Florida under a 12-month contract. We also lease approximately 2,500 square feet of business space located at 9 Palm Street, White River 1240, Mpumalanga, South Africa, which houses administrative and executive management personnel. This space is leased under a five-year term with an option to purchase. Management believes that these facilities are adequate for operations for the coming twelve months.

Item VIII - The name of the chief executive officer, members of the board of directors, as well as control persons

A. Officers and Directors

Roger Baylis-Duffield
Chief Executive Officer and Director
Compensation: $180,000 per year
Person Named above does not own any shares of the Company.

Mr. Duffield has a significant background in the development and management of start-ups, private and public companies, in the United States, Europe and South Africa. Currently, Mr. Duffield serves as CEO of Protext Mobility as well as Chairman of Plandai Biotechnology Inc., a USA public company with operations in South Africa. He also serves as the non-executive chairman of the Dunn Roman group of companies. In 2002, Mr. Duffield cofounded the Plandai group of companies, which is now comprised of considerable interests in biopharmaceuticals in South Africa, including the 7500 acre Senteeko green tea estate. He has an extensive background with published scientific research and development of Plandai sciences and bioavailable botanical extracts through the actions of cavitation and sonoluminescence relating with live plant materials and emulsions. The Plandai science platform involves contributions from numerous academic institutions and research laboratories.

Mr. Duffield was awarded in 1997 an Honorary Nuclear Doctorate by the Russian Academy of Natural Sciences and a further Honorary Doctorate in Material Sciences by the European Natural Sciences. In 2001 the Foundation for International Services, California granted recognition of a BSc qualification in Chemical Engineering. During the period 1990 through 2002 Mr. Duffield both founded and managed two USA public companies involved with new sciences relating to hydrocarbons, emulsions and fuel cells supported through powder metallurgy. Extensive published research has been undertaken with numerous academic institutions through the world, including USA, Europe, Russia, Siberia and South Africa. Mr. Duffield also has an extensive background in the farming of sub-tropical fruits and green tea when he owned and operated farms in South Africa.

David Lewis
Director, Business Development
Compensation: $120,000 per year
Person named above owns 49,500 shares of Series A Preferred stock.

B. Legal/Disciplinary History.

None of our officers or directors have been the subject of a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; a finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange

Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; the entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

The following table sets forth information regarding the beneficial ownership of our common stock with respect to each of our executive officers, each of our directors, each person known by us to own beneficially more than 5% of the common stock, and all of our directors and executive officers as a group as of June 30, 2017. Each individual or entity named has sole investment and voting power with respect to shares of common stock indicated as beneficially owned by them, except where otherwise noted.

Plandaí Biotechnology, Inc.[(1)] 17 Hanover Square London, England	Series D Preferred	90,000	100%
Steve Berman[(2)]	Series C Preferred	2,675,000	100%
Jay Safier[(2)]	Series B Preferred	46,052	100%
Rock Island Capital[(2)]	Series A Preferred	10,000	13%
Richard Grossfeld[(2)]	Series A Preferred	16,623	22%
David Lewis[(2)]	Series A Preferred	49,500	65%

(1) Plandaí Biotechnology, Inc., is majority controlled by Moor Holdings, a private trust of which Roger Baylis-Duffield and his wife are the primary beneficiaries. Mr. Baylis-Duffied is the Chairman and Chief Executive Officer of Plandaí Biotechnology, a Nevada Corporation. His address is 9 Palm Street, White River 1240, Mpumalanda, South Africa.

(2) The address for these listed individuals is 2255 Glades Road, Suite 324A, Boca Raton, Florida.

Item IX - Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

1. Investment Banker: None
2. Promoters: None
3. Counsel: Mailander Law Office, Inc.
   835 5th Avenue, Suite 312
   San Diego, CA 92101

(619)239-9034

4. Accountant or Auditor: HE Merrill Advisory
1651 North 400 East, #614
North Logan, UT 84341
(435)881-3611

5. Public Relations Consultant: None
6. Investor Relations Consultant: None
7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement: None

Item X - Issuer Certification

I, Roger Baylis-Duffield, certify that:

1. I have reviewed this quarterly disclosure statement of Protext Mobility, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated August 21, 2017

Date: /s/ *Roger Baylis-Duffield*__
Roger Baylis-Duffield
/S/ Roger Baylis-Duffield
Chief Executive Officer

Protext Pharma, Inc.
(fka Protext Mobility, Inc.)
Financial Statements
June 30, 2017
(Unaudited)

PROTEXT PHARMA, INC.
Balance Sheets as of
June 30, 2017 and December 31, 2016
(Unaudited)

	June 30, 2017	December 31, 2016
ASSETS		
Cash	20,762	-
Total Current Assets	20,762	-
Fixed Assets		
License Agreement	$ 2,170,000	$ 2,100,000
Capitalized Software Developement	433,395	433,395
Total Fixed Assets	2,603,395	2,533,395
TOTAL ASSETS	**$ 2,624,157**	**$ 2,533,395**
LIABILITIES & EQUITY		
Current Liabilities		
Accounts Payable and Accrued Expenses	$ 294,194	$ 255,170
Accrued Salary	$ 143,650	$ 77,500
Convertible Notes Payable	624,480	689,383
Payable to Related Party	506,450	485,800
Other Notes Payable	380,640	380,640
Total Current Liabilities	1,949,414	1,888,493
Total Liabilities	1,949,414	1,888,493
Equity		
Common Stock, 10,000,000,000 shares par value $0.0001 authorized, 3,089,879,479 and 1,946,690,324 issued and outstanding as of June 30, 2017 and December 31, 2016	30,899	19,467
Common Stock Issuable	116,750	-
Additional Paid-in Capital	1,384,695	1,160,880
Preferred Stock-Series A 100,000 par value $0.001 shares authorized, 76,123 shares issued and outstanding as of June 30, 2017 and December 31, 2016	76	79
Preferred Stock-Series B 1,000,000 par value $0.0001 shares authorized, 504,003 shares issued and outstanding as of June 30, 2017 December 31, 2016	1	1
Preferred Stock - Series C 9,000,000 par value $0.001 shares authorized, 2,675,0000 issued and outstanding as of June 30, 2017 and December 31, 2016	2,675	2,675
Preferred Stock - Series D 100,000 par value $0.001 shares authorized, 100,000 shares issued and outstanding as of June 30, 2017 and December 31, 2016	100	100
Retained Deficit	(869,452)	(538,300)
Total Equity	665,744	644,902
TOTAL LIABILITIES & EQUITY	**$ 2,615,158**	**$ 2,533,395**

The accompanying notes are an integral part of these consolidated financial statements.

PROTEXT PHARMA, INC.
Statements of Income
(Unaudited)

	For the Three Months Ended		For the Six Months Ended	
	June 30 2017	June 30 2016	June 30 2017	June 30 2016
Expenses				
Payroll	$ 91,100	$ -	$ 111,100	$ -
Consulting	64,960	-	89,749	-
Professional Services	31,283	-	31,283	
Research & Development	43,000	-	43,000	
General and Admin	7,839	-	25,488	-
Rent Expense	3,500	-	3,500	-
Total Expense	241,682	-	304,120	-
Net Operating Loss	(241,682)	-	(304,120)	-
Interest Expense	(27,032)	-	(27,032)	-
Net Loss	**$ (268,714)**	**$ -**	**$ (331,152)**	**$ -**

The Accompanying Notes are an Integral Part of These Consolidated Financial Statement

PROTEXT PHARMA, INC.
Statements of Equity
(Unaudited)

	Shares Outstanding	Common Stock	Series A Preferred	Series B Preferred	Series C Preferred	Series D Preferred	Paid In Capital	Stock Issuable	Retained Earnings	Total
Balance at December 31, 2015	-	-	-	-	9,000	100	1,174,047	-	(247,900)	935,247
Shares Issued on Share Exchange	1,946,690,324	19,467	79	1	(6,325)	-	(13,167)		-	55
Net Loss for Year Ended December 31, 2016	-	-	-	-	-	-	-		(290,400)	(290,400)
Balance at December 31, 2016	1,946,690,324	19,467	79	1	2,675	100	1,160,880	-	(538,300)	644,902
Shares issued on conversion of debt	1,078,189,155	10,782					165,962			176,744
Shares issued on conversion of stock	20,000,000	200	(3)				(197)			-
Shares issuabe for cash								46,750		46,750
Shares issued for services	45,000,000	450					58,050			58,500
Shares issuable to acquire subsidiary								70,000		70,000
Net Loss of the Period									(331,152)	(331,152)
Balance at June 30, 2017	3,089,879,479	$ 30,899	$ 76	$ 1	$ 2,675	$ 100	$ 1,384,695	$ 116,750	$ (869,452)	$ 665,744

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT PHARMA, INC.
Statements of Cash Flows
(Unaudited)

	Six Months Ended	
	June 30 2017	June 30 2016
Cash Used in Operations:		
Net loss	$ (331,152)	$ -
Shares issuable for services	58,500	
Non-cash Adjustments to operating accounts:		
Decrease in accounts payable and accrued expenses	39,024	
Decrease in accrued salaries	66,150	-
Decrease in related party payables	(2,510)	-
Net cash from operating activities	(169,988)	-
Cash From Financing Activities		
Proceeds from the sale of stock	46,750	-
Proceeds from the issuance of debt	144,000	-
Net cash from financing activities	190,750	-
Net Change in Cash Flow	20,762	-
Cash at beginning of period	-	-
Cash at end of period	$ 20,762	$ -
Supplemental Cash Flow Information:		
Cash Paid for -		
Interst	$ -	$ -
Taxes	$ -	$ -
Shares issued on conversion of debt	$ 176,744	$ -
Shares issuable to acquire subsidiary	$ 70,000	$ -

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
Notes to Unaudited Consolidated Financial Statements
June 30, 2017

NOTE 1 - DESCRIPTION OF BUSINESS AND GOING CONCERN

ProText Mobility Inc. (the "Company") was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, ProText Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement, and changed the corporate name to Protext Pharma, Inc. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters.

As a result of the transaction with Plandaí, the shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. While Plandaí is a legal subsidiary of the Company, Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes. Accordingly, the accompanying financial statements represent the results of operations of Plandaí Biotechnology South Africa exclusive of those of ProText Mobility. The balance sheet contains the consolidated assets and liabilities of both entities for all periods presented while the retained deficit is that of Plandaí exclusively. The shares of common stock of ProText Mobility outstanding as of the acquisition date are shown as issued as of the acquisition date while the shares issued to acquire Plandaí are shown as outstanding for all periods presented.

On March 14, 2017, the Company acquired 100% of the capital stock of Cannabis Biosciences, Inc., in exchange for 50,000,000 shares of the Company's restricted common stock. Cannabis Biosciences is engaged in the development of a non-psychoactive, full-profile cannabis extract using the Phytofare® technology for pharmaceutical applications. The operations of Cannabis Biosciences from the date of the acquisition forward have been consolidated in these financial statements.

The consolidated financial statements presented as of and for the periods ending June 30, 2017 have been prepared pursuant to Generally Accepted Accounting Principles (GAAP). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been omitted pursuant to accepted rules and regulations for smaller reporting companies, but we believe that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting of normal, recurring adjustments and disclosures necessary for a fair presentation of these statements have been included. All intercompany transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. To date, the Company has generated minimal revenue and has a history of net losses. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management's efforts have been directed towards the development and implementation of a plan to generate sufficient revenues to cover all of its present and future costs and expenses.

If the Company does not generate sufficient revenues from the sales of its products in an amount necessary to meet its cash needs, the Company will need additional financing to continue to operate. There are no assurances that the Company can continue to successfully raise additional financing. If the Company fails to raise additional financing, it might have to file for reorganization under bankruptcy laws to satisfy its outstanding liabilities.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included.

Use of Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. We regularly evaluate our estimates and assumptions related to the useful life and recoverability of long-lived assets, stock-based compensation and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations will be affected.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired, to be cash equivalents.

Income Taxes

The Company accounts for income taxes under the provisions issued by the FASB which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company computes tax asset benefits for net operating losses carried forward. The potential benefit of net operating losses has not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Fair Value of Financial Instruments

Pursuant to ASC No. 820, “Fair Value Measurements and Disclosures”, the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of December 31, 2016 and 2015. The Company’s financial instruments consist of cash and derivative liabilities. The Company considers the carrying value of such amounts in the financial statements to approximate their fair value due to the short-term nature of these financial instruments.

The Company adopted ASC No. 820-10 (ASC 820-10), Fair Value Measurements. ASC 820-10 relates to financial assets and financial liabilities. ASC 820-10 defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (GAAP), and expands disclosures about fair value measurements. The provisions of this standard apply to other accounting pronouncements that require or permit fair value measurements and are to be applied prospectively with limited exceptions.

ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This standard is now the single source in GAAP for the definition of fair value, except for the fair value of leased property as defined in SFAS 13. ASC 820-10 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions, about market participant assumptions, that are developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

- Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

- Level 3 Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. (The unobservable inputs are developed based on the best information available in the circumstances and July include the Company's own data.)

The following presents the Company's fair value hierarchy for those assets and liabilities measured at fair value on a non-recurring basis as of June 30, 2017 and December 31, 2016:

June 30, 2016:

	Level 1	**Level 2**	**Level 3**	**Total**
	$ -	$ -	$ -	$ -
Total	$ -	$ -	$ -	$ -

December 31, 2016:

	Level 1	**Level 2**	**Level 3**	**Total**
	$ -	$ -	$ -	$ -
Total	$ -	$ -	$ -	$ -

<u>Derivative Financial Instruments</u>

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.

As of June 30, 2017 the fair value of the embedded derivative instruments was not considered material as all convertible instruments have fixed-price conversion features.

Research and Development Costs

Costs incurred in the research and development during the preliminary project stage are expensed as incurred. Costs specifically attributable to clinical trials are capitalized and amortized over the expected life of the product. During the six months ended June 30, 2017, the company expensed $43,000 in research costs.

Prior to 2015, the Company capitalized a total of $433,395 associated with software development by ProText Mobility. The Company is evaluating this asset for potential impairment.

NOTE 3 – PAYABLE TO RELATED PARTIES

Payables to related parties includes operational costs of $230,400 paid by the Company's majority shareholder, Plandaí Biotechnology, Inc. on behalf of the Company during each of the years ended December 31, 2016 and 2015, for a total of $460,800 as of December 31, 2016. It is anticipated that these costs will be reimbursed once the Company achieves profitable operations. As of June 30, 2017, a total of 481,450 was owed to Plandaí.

The Company had senior secured convertible notes payable to one of its directors, amounting to $25,000 at December 31, 2016, December 31, 2015 and December 31, 2014. This class of notes bears interest at 10% and is convertible at the lesser of 60% of the weighted-average price for the 5-day immediately prior to the conversion or the lowest conversion price of the 120-day period prior to conversion, but no less than the par value. As of December 31, 2016, all accrued interest was forgiven and the parties agreed to suspend the accumulation of interest until July 1, 2017. The notes are currently due.

NOTE 4 - CONVERTIBLE NOTES PAYABLE

In prior years, the Company issued convertible notes payable to various individuals and funds, of which $388,480 remain issued and outstanding. As of December 31, 2016, the Company had negotiated with most of the convertible debt holders to eliminate all accrued interest and penalties and place a moratorium on future interest payments and conversions for a period of at least six months. Future conversions will not involve any discount off the then-trading price of the common stock. As a result, the derivative liability associated with these notes was deemed immaterial and all discounts and derivative liabilities were eliminated. During the six months ended June 30, 2017, the Company converted $176,744 of principal and interest.

The Company had senior secured convertible notes payable to the father of one of the directors amounting to $92,000 at December 31, 2016, December 31, 2015 and December 31, 2014. This class of notes bears interest at 10% and is convertible at the lesser of 60% of the weighted-average price for the 5-day immediately prior to the conversion or the lowest conversion price of the 120-day period prior to conversion, but no less than the par value. As of December 31, 2016, all accrued interest was forgiven and the parties agreed to suspend the accumulation of interest until July 1, 2017. During the quarter ended March 31, 2017, the Company converted $4,800 of this debt.

During the six months ended June 30, 2017, the Company issued a total of $144,000 in convertible notes. Notes totaling $119,000 were issued to one entity in four separate notes, $26,000 on January 31, $26,000 on February 8, $51,000 on March 2, and $16,000 on March 28, respectively. Each of these notes matures 12 months from the date of issuance and is convertible into shares of common stock at a 35% discount based on the average of the lowest three closing bid prices over the previous 10 days, with a floor of $0.000065 per share.

On June 14, 2017, the Company issued a convertible note in the amount of $25,000 to an unrelated party. The note bears interest at 8% and is convertible at a 50% discount based on the average of the lowest three closing bid prices over the previous 10 days, with a floor of $0.000065 per share.

NOTE 5 – OTHER NOTES PAYABLE

In prior years, the Company issued several notes payable of which $380,640, including accrued interest, remain payable as of December 31, 2016, and 2015. These notes are current due and payable and earn interest at the rate of 10% per annum. The Company has the option of converting these notes into common stock at a discount of 35% off the trading price on the date of conversion.

NOTE 6 - EQUITY TRANSACTIONS

Common Stock

The Company has authorized 10 billion shares of common stock, par value $0.00001, of which 3,089,879,479 shares were issued and outstanding as of June 30, 2017. During the six months ended June 30, 2017, a total of 1,143,189,155 shares of common stock were issued, as follows:

- 45,000,000 shares were issued for services valued at $58,500
- 1,078,189,155 shares were issued on the conversion of $176,744 in notes payable
- 20,000,000 shares were issued on the conversion of 3,327 shares of Series A Preferred stock

In addition, the Company is obligated to issue 31,000,000 shares of common stock resulting from cash sales of $46,750 and 50,000,000 shares of common stock as consideration for acquiring Cannabis Biosciences, Inc. The value of these shares, $116,750, has been recorded as Stock Payable in the financial statements.

Series A Preferred

The Company has 100,000 shares of Series A Preferred stock, par value $0.001, authorized of which 79,450 shares were issued on December 31st, 2016 in exchange of 504,300 shares of Series B Preferred, previously issued. Of this amount, 10,000, 19,950 and 49,500 Series A were issued to Rock Island, Richard Grossfeld and David Lewis respectively, in exchange for 411,899, 46,052 and 46,052 Series B previously issued and held by each party respectively. The Series A Preferred has conversion rights equal to 20% of the post-conversion issued and outstanding shares of common stock and voting rights equivalent to the total shares issuable on conversion. On June 12, 2017, Mr. Grossfeld converted 3,327 shares of Series A into 20,000,000 shares of common stock in accordance with the terms of conversion. As of June 30, 2017, there were 76,123 shares of Series A issued and outstanding.

Series B Preferred

The Company previously issued 550,055 shares of Series B Preferred stock for cash consideration of $4,825,000. On December 31, 2016, the Company exchanged 504,003 shares of Series B Preferred stock into 79,450 shares of Series A Preferred, leaving 46,052 shares of Series B Preferred stock outstanding. The Series B Preferred has voting rights equal to two votes per share on all shareholder matters and has a preference on dividend payments.

Series C Preferred

The Company has authorized 9,000,000 shares of Series C Preferred stock, par value $0.001, of which 9,000,000 were previously issued. On December 31, 2016, the holder of 6,325,000 shares of Series C Preferred returned the shares for cancellation in connection with the share exchange with Plandaí. The Series C have voting rights equal to 200 votes per share on all shareholder matters.

Series D Preferred

On December 31, 2016, the Company issued 100,000 shares of Series D Preferred stock to acquire 100% of the issued and outstanding capital stock of Plandaí Biotechnology South Africa (Pty) Ltd. There are 100,000 shares of Series D Preferred stock, par value $0.001, of which 100,000 and 0 were outstanding as of December 31, 2016 and 2015, respectively. The Series D Preferred stock has conversion rights equal to 75% of the post-conversion common stock and voting rights equivalent to the number of shares issuable on conversion.

NOTE 7- SUBSEQUENT EVENTS

The Company reviewed transactions subsequent to June 30, 2017 and noted no material events apart from the following:

- A total of 255,000,000 shares of common stock were issued on the conversion of $56,000 in notes payable and associated interest

- The Company sold 75,000,000 of restricted common stock to an accredited investor for proceeds of $15,000.